The efficacy of adjunctive mitomycin C and/or anti-VEGF agents on glaucoma tube shunt drainage device surgeries: a systematic review.
Raquel FigueiredoJoão Barbosa BredaPublished in: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2024)
There is no high-quality evidence to support the use of MMC in tube shunt surgery. As for anti-VEGF agents, specifically bevacizumab, significant benefit seems to exist in neovascular glaucoma patients, especially if combined with PRP.
Keyphrases
- vascular endothelial growth factor
- end stage renal disease
- ejection fraction
- endothelial cells
- newly diagnosed
- pulmonary artery
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- age related macular degeneration
- ultrasound guided
- coronary artery disease
- acute coronary syndrome
- pulmonary hypertension
- cataract surgery
- metastatic colorectal cancer
- surgical site infection
- optical coherence tomography